Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00802074 · ClinicalTrials.gov registry record · NA
An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects
A NA study of Healthy, sponsored by Garden State Infectious Disease Associates, PA.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT00802074: Completed NA study of Healthy, sponsored by Garden State Infectious Disease Associates, PA.
NCT00802074 is a NA study of Healthy that has completed, run by Garden State Infectious Disease Associates, PA. The registered enrollment target is 45 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00802074, a NA study of Healthy, has completed, sponsored by Garden State Infectious Disease Associates, PA.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
To date, no study has investigated whether there is a drug interaction between the protease inhibitor fosamprenavir and the integrase inhibitor raltegravir. COL112775 is a randomized, open-label, 6-arm, 3-period, drug interaction study to assess steady-state plasma amprenavir (APV) and raltegravir (RTG) pharmacokinetics in 48 healthy, fasting, HIV-negative adults after administration of a 7-day regimen of RTG 400mg BID alone and after 14-day regimens of unboosted fosamprenavir (FPV) 1400mg twice daily (BID), FPV 700mg/RTV 100mg BID, or FPV 1400mg/ritonavir (RTV) 100mg once daily (QD) with and without concurrent RTG 400mg BID. Blood samples for drug concentration measurement will be collected over 12 hours at the end of each dosing period. Subjects will undergo a physical examination, complete blood count (CBC) with differential, HIV test, hepatitis B/C test, liver function test, renal function analysis, and lipid panel at screening, and all of these tests, except those for HIV and hepatitis B/C, will be repeated at follow-up post-study. Adverse events and adherence (by pill count and medication diary) will be assessed by the investigator/study personnel at the end of each dosing period
Conditions Studied
Interventions
- DRUG Ritonavir
- DRUG Raltegravir
- DRUG Fosamprenavir
Study Locations (1)
New Jersey
- Garden State Infectious Disease Associates, PA - Voorhees Township
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00802074
The ClinicalTrials.gov registry entry for NCT00802074 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (93% lower). The listed sponsor is Garden State Infectious Disease Associates, PA, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Ritonavir is the first listed.
NCT00802074 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00802074 about?
NCT00802074 is a clinical study titled "An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects". To date, no study has investigated whether there is a drug interaction between the protease inhibitor fosamprenavir and the integrase inhibitor raltegravir. COL112775 is a randomized, open-label, 6-arm, 3-period, drug interaction study to assess steady-state plasma amprenavir (APV) and raltegravir (...
What is the current status of trial NCT00802074?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2008-12. Estimated completion is 2009-04.
What conditions does trial NCT00802074 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT00802074?
The interventions under investigation include: Ritonavir (DRUG), Raltegravir (DRUG), Fosamprenavir (DRUG).
Who is sponsoring clinical trial NCT00802074?
This trial is sponsored by Garden State Infectious Disease Associates, PA, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00802074 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
-
Oxalate and Citrate in Humans - Response to Citrate
RECRUITING · NA
-
CArdioMEtabolic Function and Reserve Capacity in Healthy Adults: The CAMERA Study
RECRUITING · NA
-
Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia
RECRUITING · NA
-
Medical Illustration Design Characteristic Evaluation
RECRUITING · NA
-
Sodium vs Potassium Education to Improve Vascular Health
RECRUITING · NA
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.